ALK and non-small cell lung carcinoma: Due to the relative low incidence of ALK-positive NSCLC and rare proportion of phenotypic transformation after ALK-tyrosine kinase inhibitor (TKI) resistance, there are no large clinical study reports that detail the clinical coping strategies and prognosis in this group of patients.